Petrelintide 2026: ZUPREME-1 Phase 2 Data, Roche/Zealand Phase 3 Plans & Cagrilintide Comparison

Petrelintide, the amylin analog behind Zealand Pharma and Roche's $5.3B collaboration, posted 10.7% weight loss and near-zero vomiting in Phase 2. Heres the ZUPREME-1 data, Phase 3 timeline, and how it stacks up against cagrilintide.